Arvinas (ARVN) closed at $6.41 on November 6, 2026, down 2.1% from the previous close, on volume of 1,123,856 shares (30-day average 767,209).
Data as of November 6, 2026.
6-Nov-2026
Arvinas Holding Company (ARVN) Receives a Hold from Leerink Partners
TipRanks (Thu, 5-Nov 9:31 AM ET)
AI-Driven Drug Discovery at Arvinas: Operational Risks, Regulatory Pressures, and Financial Fallout
TipRanks (Thu, 5-Nov 1:01 AM ET)
Globe Newswire (Wed, 4-Nov 4:01 PM ET)
Wells Fargo Reaffirms Their Hold Rating on Arvinas Holding Company (ARVN)
TipRanks (Wed, 4-Nov 9:01 AM ET)
Piper Sandler Remains a Buy on Arvinas Holding Company (ARVN)
TipRanks (Wed, 4-Nov 9:01 AM ET)
Arvinas’ Buy Rating Reaffirmed as Pipeline Catalysts Support Unchanged $18 Price Target
TipRanks (Wed, 4-Nov 8:37 AM ET)
Arvinas Holding Company (ARVN) Receives a Buy from Barclays
TipRanks (Wed, 4-Nov 3:59 AM ET)
Arvinas Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Globe Newswire (Tue, 3-Nov 7:00 AM ET)
Globe Newswire (Tue, 27-Oct 4:01 PM ET)
Arvinas to Report Third Quarter 2026 Financial Results on November 3, 2026
Globe Newswire (Tue, 27-Oct 7:00 AM ET)
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
Arvinas trades on the NASDAQ stock market under the symbol ARVN.
As of November 6, 2026, ARVN stock price declined to $6.41 with 1,123,856 million shares trading.
ARVN has a beta of 1.74, meaning it tends to be more sensitive to market movements. ARVN has a correlation of 0.17 to the broad based SPY ETF.
ARVN has a market cap of $419.13 million. This is considered a Small Cap stock.
Last quarter Arvinas reported $500,000 in Revenue and -$.82 earnings per share. This fell short of revenue expectation by $-18 million and exceeded earnings estimates by $.10.
In the last 3 years, ARVN traded as high as $53.08 and as low as $5.90.
The top ETF exchange traded funds that ARVN belongs to (by Net Assets): VTI, IWM, VXF, IWN, XPH.
ARVN has underperformed the market in the last year with a price return of -35.9% while the SPY ETF gained +10.8%. ARVN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -26.2% and -12.2%, respectively, while the SPY returned -4.1% and -3.2%, respectively.
ARVN support price is $6.27 and resistance is $6.83 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ARVN shares will trade within this expected range on the day.